These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 31813930)

  • 21. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
    Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
    Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA
    J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.
    Kanigicherla D; Gummadova J; McKenzie EA; Roberts SA; Harris S; Nikam M; Poulton K; McWilliam L; Short CD; Venning M; Brenchley PE
    Kidney Int; 2013 May; 83(5):940-8. PubMed ID: 23364522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of 3 anti-PLA2R inmmunoassaysfor the diagnosis of idiopathic membranous nephropathy in an european population. A pilot study.
    Nieto-Gañán I; Rita CG; Villacorta-Pérez J; Ortego-Pérez S; Rodríguez-Mendiola N; Carrasco-Sayalero Á
    Clin Immunol; 2021 Jun; 227():108729. PubMed ID: 33872763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
    Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
    J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
    Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
    Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy.
    Tian C; Li L; Liu T; Qu X; Qiu Y
    Int Urol Nephrol; 2019 Aug; 51(8):1371-1377. PubMed ID: 31227982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Glomerular Mannose-Binding Lectin Deposition on the Prognosis of Idiopathic Membranous Nephropathy.
    Zhang Y; Liu Y; Liang L; Liu L; Tang X; Tang L; Chen P; Chen J; Wang Z; Cao W; Chen Q; Zhao N; Xu D
    Kidney Blood Press Res; 2020; 45(5):713-726. PubMed ID: 32894840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China.
    Guo H; Yao Y; Zhou J; Wang S; Wang Y; Zheng D
    Ren Fail; 2023; 45(2):2253922. PubMed ID: 37724562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
    Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
    Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic efficacy of serum anti-phospholipase A2 receptor antibodies for idiopathic membranous nephropathy in patients with diabetic kidney disease.
    Wang Q; Dong ZY; Zhang WG; Liu XM; Qu YL; Duan SW; Huang MJ; Zhou JH; Chen P; Zhu HY; Zhang L; Sun XF; Cai GY; Chen XM
    Clin Chim Acta; 2020 Mar; 502():222-226. PubMed ID: 31730818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy.
    Liu L; Chang B; Wu X; Guo Y; Pan Y; Yang L
    Vasc Health Risk Manag; 2018; 14():103-108. PubMed ID: 29881283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
    Hoxha E; Thiele I; Zahner G; Panzer U; Harendza S; Stahl RA
    J Am Soc Nephrol; 2014 Jun; 25(6):1357-66. PubMed ID: 24610926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    PLoS One; 2014; 9(10):e110681. PubMed ID: 25313791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.
    Hoxha E; Kneißler U; Stege G; Zahner G; Thiele I; Panzer U; Harendza S; Helmchen UM; Stahl RA
    Kidney Int; 2012 Oct; 82(7):797-804. PubMed ID: 22673885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum phospholipase A2 receptor antibodies and immunoglobulin G subtypes in adult idiopathic membranous nephropathy: Clinical value assessment.
    Cheng G; Liu J; Gilbert A; Cao Y; An C; Lv Z; Wang C; Nie R; Zhang J; Liu Y; Xia M; Li S; Cai H; Li Y; Li Y; Qin X
    Clin Chim Acta; 2019 Mar; 490():135-141. PubMed ID: 30605630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
    Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
    Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
    Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
    Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
    [No Abstract]   [Full Text] [Related]  

  • 40. The optimal anti-phospholipase A2 receptor cutoff for the diagnosis of idiopathic membranous nephropathy: a single-center retrospective study.
    Li C; Li P; Guo W; Chen L; Li J; Wang R; Chen B
    Korean J Intern Med; 2022 Jan; 37(1):154-166. PubMed ID: 32972118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.